Evan H Einstein1, Nicholas B Dadario2, Hamza Khilji3, Justin W Silverstein4,5, Michael E Sughrue6, Randy S D'Amico3. 1. Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA. eeinstein@northwell.edu. 2. Robert Wood Johnson School of Medicine, Rutgers University, New Brunswick, NJ, USA. 3. Department of Neurological Surgery, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA. 4. Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA. 5. Neuro Protective Solutions, New York, NY, USA. 6. Centre for Minimally Invasive Neurosurgery, Prince of Wales Private Hospital, Sydney, NSW, Australia.
Abstract
INTRODUCTION: Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. METHODS: We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. RESULTS: Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. CONCLUSIONS: Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.
INTRODUCTION: Transcranial magnetic stimulation (TMS) is a neuromodulation technology capable of targeted stimulation and inhibition of cortical areas. Repetitive TMS (rTMS) has demonstrated efficacy in the treatment of several neuropsychiatric disorders, and novel uses of rTMS for neurorehabilitation in patients with acute and chronic neurologic deficits are being investigated. However, studies to date have primarily focused on neurorehabilitation in stroke patients, with little data supporting its use for neurorehabilitation in brain tumor patients. METHODS: We performed a review of the current available literature regarding uses of rTMS for neurorehabilitation in post-operative neuro-oncologic patients. RESULTS: Data have demonstrated that rTMS is safe in the post-operative neuro-oncologic patient population, with minimal adverse effects and no documented seizures. The current evidence also demonstrates potential effectiveness in terms of neurorehabilitation of motor and language deficits. CONCLUSIONS: Although data are overall limited, both safety and effectiveness have been demonstrated for the use of rTMS for neurorehabilitation in the neuro-oncologic population. More randomized controlled trials and specific comparisons of contralateral versus ipsilateral rTMS protocols should be explored. Further work may also focus on individualized, patient-specific TMS treatment protocols for optimal functional recovery.
Authors: A Berardelli; M Inghilleri; J C Rothwell; S Romeo; A Currà; F Gilio; N Modugno; M Manfredi Journal: Exp Brain Res Date: 1998-09 Impact factor: 1.972
Authors: Mark S George; Sarah H Lisanby; David Avery; William M McDonald; Valerie Durkalski; Martina Pavlicova; Berry Anderson; Ziad Nahas; Peter Bulow; Paul Zarkowski; Paul E Holtzheimer; Theresa Schwartz; Harold A Sackeim Journal: Arch Gen Psychiatry Date: 2010-05
Authors: M S George; E M Wassermann; T A Kimbrell; J T Little; W E Williams; A L Danielson; B D Greenberg; M Hallett; R M Post Journal: Am J Psychiatry Date: 1997-12 Impact factor: 18.112
Authors: John P O'Reardon; H Brent Solvason; Philip G Janicak; Shirlene Sampson; Keith E Isenberg; Ziad Nahas; William M McDonald; David Avery; Paul B Fitzgerald; Colleen Loo; Mark A Demitrack; Mark S George; Harold A Sackeim Journal: Biol Psychiatry Date: 2007-06-14 Impact factor: 13.382
Authors: Jean-Pascal Lefaucheur; Nathalie André-Obadia; Andrea Antal; Samar S Ayache; Chris Baeken; David H Benninger; Roberto M Cantello; Massimo Cincotta; Mamede de Carvalho; Dirk De Ridder; Hervé Devanne; Vincenzo Di Lazzaro; Saša R Filipović; Friedhelm C Hummel; Satu K Jääskeläinen; Vasilios K Kimiskidis; Giacomo Koch; Berthold Langguth; Thomas Nyffeler; Antonio Oliviero; Frank Padberg; Emmanuel Poulet; Simone Rossi; Paolo Maria Rossini; John C Rothwell; Carlos Schönfeldt-Lecuona; Hartwig R Siebner; Christina W Slotema; Charlotte J Stagg; Josep Valls-Sole; Ulf Ziemann; Walter Paulus; Luis Garcia-Larrea Journal: Clin Neurophysiol Date: 2014-06-05 Impact factor: 3.708